Printer Friendly

CIBA-GEIGY PHARMACEUTICALS DIVISION ISSUES STATEMENT ON NICOTINE PATCHES AND HEART ATTACK

 CIBA-GEIGY PHARMACEUTICALS DIVISION ISSUES STATEMENT
 ON NICOTINE PATCHES AND HEART ATTACK
 SUMMIT, N.J., June 19 /PRNewswire/ -- The Pharmaceuticals Division of Ciba-Geigy Corporation issued the following statement today:
 We are concerned about the patients who have experienced heart attacks while smoking and using a nicotine patch, one of which is Habitrol (R), marketed by Ciba-Geigy.
 It is well known that smokers already face a significantly increased risk for heart attack. Wearing the nicotine patch does not protect a person from the accumulated risk incurred from years of smoking.
 We are looking carefully at the issue of heart attack among patients who smoke while using nicotine patches. Our medical evaluation has two components. First, we are studying the case records of the patients who have been reported to us as having had a heart attack while using the nicotine patch. By examining their medical histories, we may be able to gain a better understanding about the cause of their heart attack.
 Secondly, we will be continuing and expanding our research program of clinical trials and epidemiologic studies to study the effect of Habitrol in smokers with known coronary artery disease.
 We welcome this opportunity to reinforce the proper usage of the patch, specifically as stated in the patient instructions (which come in every box of Habitrol): "You should not smoke while using the Habitrol patch."
 Additionally, we are instructing our medical representatives who call on individual physicians to continue to emphasize the importance of advising their patients not to smoke while using Habitrol.
 -0- 6/19/92
 /CONTACT: Doug Arbesfeld of Ciba-Geigy, 908-277-5758/ CO: Ciba-Geigy Corporation ST: New Jersey IN: MTC SU:


LR-AH -- NY071 -- 2096 06/19/92 17:20 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 19, 1992
Words:280
Previous Article:SOUTHERN CALIFORNIA REAL ESTATE OBSERVER REPORTS SOUTHERN CALIFORNIA HOME SALES
Next Article:CARNIVAL CRUISE LINES FILES REGISTRATION STATEMENT FOR $100 MILLION OF CONVERTIBLE SUBORDINATED NOTES
Topics:


Related Articles
NICOTINE SKIN PATCH AVAILABLE FOR SMOKING CESSATION
LEDERLE LABORATORIES ISSUES A STATEMENT ON PROSTEP
SIX STEPS HELP SMOKERS QUIT AND STAY SMOKE-FREE
CIBA PHARMACEUTICALS ISSUES STATEMENT ON RITALIN SHORTAGE
NEW DOSAGE STRENGTH FOR NITROGLYCERINE PATCH ANNOUNCED
COURT RULES IN FAVOR OF ALZA & MARION MERRELL DOW, DECLARES CIBA-GEIGY NICOTINE PATENT INVALID
CIBA TO TRANSFER MARKETING OF NICOTINE PATCH TO CONSUMER UNIT
COURT RULES IN FAVOR OF ALZA & HOECHST MARION ROUSSEL
HOECHST MARION ROUSSEL, ALZA CORPORATION AND CIBA-GEIGY SETTLE NICOTINE PATCH PATENT LITIGATION
Glaxo Wellcome Inc. Announces FDA Clearance of the First Nicotine-Free Prescription Medicine to Help People Quit Smoking

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters